Influenza
Conditions
Keywords
H1N1, influenza A viruses, TIV, vaccine, infants, children
Brief summary
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine against the 2009 H1N1 virus. This study will help determine how and when the H1N1 flu shot should be given with the seasonal flu shot to make it most effective. The 650 participants will be divided into the following age groups: infants from 6 months-36 months old, children 36 months-9 years old, and adolescents 10-17 years old. Each age group will have 200 children. There are 4 treatment groups in each age level. Study procedures include: medical history, targeted physical exam based on history, maintaining a memory aid, and blood sample collection. Participants will be involved in the study for about 8 months.
Detailed description
Recently, a novel swine-origin influenza A/H1N1 virus was identified as a significant cause of febrile respiratory illnesses in Mexico and the United States. It rapidly spread to many countries around the world, prompting the World Health Organization (WHO) to declare a pandemic on June 11, 2009. Data from several cohorts in different age groups that received licensed trivalent seasonal influenza vaccines suggest that these vaccines are unlikely to provide protection against the new virus. In addition, adults are more likely to have measurable levels of serum hemagglutination inhibition assay (HAI) or neutralizing antibody than are children. These data indicate the need to develop vaccines against the new H1N1 strain and suggest that different vaccine strategies (e.g., number of doses, need for adjuvant) may be appropriate for persons in different age groups. If the novel influenza H1N1 2009 virus continues to circulate, it is possible that it will co-circulate with the non-pandemic seasonal influenza strains. In this situation, it might be beneficial to co-administer an H1N1 vaccine concurrent with the seasonal inactivated influenza vaccine. This protocol will explore if vaccination with the 2009-2010 licensed seasonal trivalent influenza vaccine (TIV) has an effect on antibody response to the novel influenza H1N1 2009 virus. This protocol will also examine if receiving the H1N1 vaccine either concurrent with, prior to, or following the seasonal influenza vaccine affects the antibody response to the seasonal influenza vaccine. A randomized Phase II study in infants, toddlers, children and adolescents. This study is designed to investigate the safety, reactogenicity, and immunogenicity of an inactivated influenza H1N1 virus vaccine when given concurrent with seasonal TIV, or sequentially with (before or after) seasonal influenza vaccine. Primary objectives are: safety, to assess the safety of the unadjuvanted, inactivated H1N1 vaccine when administered either concurrent with, prior to, or following licensed seasonal influenza vaccination; and immunogenicity, to assess the effect of TIV administration on antibody response to unadjuvanted, inactivated H1N1 vaccine as assessed by HAI, stratified by age of recipient. The secondary objective is: immunogenicity, to assess the effect of H1N1 vaccine administration on antibody response to TIV as assessed by HAI, stratified by age of recipient. Subjects will be randomized into 4 groups, stratified by age (150 subjects per group with 50 subjects per age stratum: greater than or equal to 6-\<36 months, greater than or equal to 36 months-9 years, and 10-17 years), to receive two 15 mcg doses of inactivated influenza H1N1 vaccine at Days 0 and 21 followed by TIV on Day 42 (Group 1), two 15 mcg doses of H1N1 vaccine of which the first dose is administered concurrently with TIV (Group 2), two 15 mcg doses of H1N1 vaccine of which the second dose is administered concurrently with TIV (Group 3), or TIV administered on Day 0 followed by two 15 mcg doses of H1N1 vaccine on Days 21 and 42 (Group 4). Following immunization, safety will be measured by assessment of adverse events for 21 days following the last vaccination (Day 42 for those who do not receive the second dose), serious adverse events and new-onset chronic medical conditions for 8 months post first vaccination (Day 201 for Groups 2 and 3 or Day 222 for Groups 1 and 4), and reactogenicity to the vaccines for 8 days following each vaccination (Day 0-7). Immunogenicity testing will include HAI and neutralizing antibody testing prior to vaccination, on the day of each vaccination (Days 0, 21 and 42) and 21 days following the third vaccine.
Interventions
BIOLOGICALInactivated H1N1 Vaccine
Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
BIOLOGICALTrivalent Inactivated Influenza Vaccine
Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - \<36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 17 Years
Healthy volunteers
Yes
Inclusion criteria
* Are males or non-pregnant females aged 6 months to 17 years, inclusive. * All subjects 6 months to 9 years must be primed. * Subjects of child-bearing potential must agree to practice adequate contraception that may include, but is not limited to, abstinence, barrier methods such as condoms, diaphragms, spermicides, intrauterine devices, and licensed hormonal methods during the study for at least 30 days following the last vaccination. * The subject must be in good health, as determined by axillary (\<10 years of age) or oral temperature (axillary temperature \<100 degrees Fahrenheit or oral temperature \<101 degrees Fahrenheit), medical history, and targeted physical examination based on medical history. * Subject and/or parent(s)/legal guardian(s) must be willing and able to comply with planned study procedures and be available for all study visits. * Subject and/or parent(s)/legal guardian(s) must provide written informed consent prior to initiation of any study procedures, and subject may provide written assent as appropriate.
Exclusion criteria
* Have a known allergy to eggs or other components of the vaccine (including gelatin, formaldehyde, octoxinol, thimerosal and chicken protein). * Have a positive urine or serum pregnancy test within 24 hours prior to vaccination or are breastfeeding. * Have immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months. * Have an active neoplastic disease or a history of any hematologic malignancy. * Have long term use of glucocorticoids including oral, parenteral or high-dose inhaled steroids (\>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months. (Nasal and topical steroids are allowed.) * Have a diagnosis of schizophrenia, bipolar disease, or other major psychiatric diagnosis or major depression. * Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others. * Are receiving any psychiatric drugs (aripiprazole, clozapine, ziprasidone, haloperidol, molindone, loxapine, thioridazine, thiothixene, pimozide, fluphenazine, risperidone, mesoridazine, quetiapine, trifluoperazine, chlorprothixene, chlorpromazine, perphenazine, trifluopromazine, olanzapine, carbamazepine, divalproex sodium, lithium carbonate or lithium citrate) or any drugs for treatment of depression. * Have a history of receiving immunoglobulin or other blood product within the 3 months prior to vaccination in this study. * Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during the study period (prior to Day 180 after the last vaccination). * Have received any live licensed vaccines within 4 weeks or inactivated licensed vaccines within 2 weeks prior to vaccination in this study or plan receipt of such vaccines within 21 days following the last vaccination. This is inclusive of routine childhood immunizations provided outside the scope of this study. The initiation of this protocol does not take precedence over routine immunizations. * Has received a licensed 2009-2010 seasonal influenza vaccine. * Have an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe, or would interfere with the evaluation of responses. * Have a history of severe reactions following previous immunization with influenza virus vaccines. * Have an acute illness, including an axillary temperature greater than 100 degrees Fahrenheit or an oral temperature greater than or equal to 101 degrees Fahrenheit, within 3 days prior to vaccination. * Have any condition that would, in the opinion of the site investigator, place them at an unacceptable risk of injury or render them unable to meet the requirements of the protocol. * Participated in a novel influenza H1N1 2009 vaccine study in the past two years or have a history of novel influenza H1N1 2009 infection prior to enrollment. * Have known active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection. * Have a history of alcohol or drug abuse. * Plan to travel outside of North America in the time between the first vaccination and 63 days following the first vaccination. * Have a history of Guillain-Barré Syndrome. * Have any condition that the investigator believes may interfere with successful completion of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | Day 21 after first H1N1 vaccination | Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, this timepoint is Study Day 42, all others it is Study Day 21. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Within 8 days (Day 0-7) post first H1N1 vaccination | Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they were reported as experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Within 8 days (Day 0-7) post first H1N1 vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Within 8 days (Day 0-7) post first H1N1 vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Within 8 days (Day 0-7) post second H1N1 vaccination | Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they were reported as experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Within 8 days (Day 0-7) post second H1N1 vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Within 8 days (Day 0-7) post second H1N1 vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Within 8 days (Day 0-7) post TIV vaccination | Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they were reported as experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Within 8 days (Day 0-7) post TIV vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Within 8 days (Day 0-7) post TIV vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3. |
| Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) | Day 0 through 180 days after the last vaccination | Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required in-patient hospitalization or prolongation thereof; resulted in a congenital anomaly/birth defect; may have jeopardized the participant or required intervention to prevent one of these outcomes; or was described as Guillain-Barré Syndrome. Association to vaccination was determined by a study clinician licensed to make medical diagnoses. |
| Number of Participants Age 6 Months to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | Day 21 after first H1N1 vaccination | Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, this timepoint is Study Day 42, all others it is Study Day 21. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | Day 21 after first H1N1 vaccination | Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, this timepoint is Study Day 42, all others it is Study Day 21. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Number of Participants Age 6 Months to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | Day 0 prior to vaccination and 21 days after the first H1N1 vaccination | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post first H1N1 vaccination is Study Day 42 for Group 4, and is Study Day 21 for all other groups. |
| Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | Day 0 prior to vaccination and 21 days after the first H1N1 vaccination | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post first H1N1 vaccination is Study Day 42 for Group 4, and is Study Day 21 for all other groups. |
| Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | Day 0 prior to vaccination and 21 days after the first H1N1 vaccination | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post first H1N1 vaccination is Study Day 42 for Group 4, and is Study Day 21 for all other groups. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Within 8 days (Day 0-7) post first vaccination | Participants' parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of irritability, decreased appetite and lethargy for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Within 8 days (Day 0-7) post first vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Within 8 days (Day 0-7) post first vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Within 8 days (Day 0-7) post second vaccination | Participants' parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of irritability, decreased appetite and lethargy for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Within 8 days (Day 0-7) post second vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Within 8 days (Day 0-7) post second vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Within 8 days (Day 0-7) post third vaccination | Participants' parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of irritability, decreased appetite and lethargy for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Groups 1 and 4 only had a third vaccination day. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Within 8 days (Day 0-7) post third vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Groups 1 and 4 only had a third vaccination day. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Within 8 days (Day 0-7) post third vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Groups 1 and 4 only had a third vaccination day. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Within 8 days (Day 0-7) post first vaccination | Participants' parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Within 8 days (Day 0-7) post first vaccination | Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Within 8 days (Day 0-7) post first vaccination | Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Within 8 days (Day 0-7) post second vaccination | Participants' parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Within 8 days (Day 0-7) post second vaccination | Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Within 8 days (Day 0-7) post second vaccination | Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Within 8 days (Day 0-7) post third vaccination | Participants' parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. Groups 1 and 4 only had a third vaccination day. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Within 8 days (Day 0-7) post third vaccination | Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. Groups 1 and 4 only had a third vaccination day. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Within 8 days (Day 0-7) post third vaccination | Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. Groups 1 and 4 only had a third vaccination day. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Within 8 days (Day 0-7) post first H1N1 vaccination | Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Within 8 days (Day 0-7) post first H1N1 vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Within 8 days (Day 0-7) post first H1N1 vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Within 8 days (Day 0-7) post second H1N1 vaccination | Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Within 8 days (Day 0-7) post second H1N1 vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Within 8 days (Day 0-7) post second H1N1 vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4. |
| Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Within 8 days (Day 0-7) post TIV vaccination | Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3. |
| Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Within 8 days (Day 0-7) post TIV vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3. |
| Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Within 8 days (Day 0-7) post TIV vaccination | Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | Day 0 prior to first vaccination and Day 21 after last vaccination | Blood was collected from participants for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the titer at 21 days after last vaccination was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the titer at 21 days after last vaccination was an increase by 4-fold or more. Day 21 after last vaccination was study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3. |
| Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | Day 0 prior to first vaccination and Day 21 after last vaccination | Blood was collected from participants for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the titer at 21 days after last vaccination was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the titer at 21 days after last vaccination was an increase by 4-fold or more. Day 21 after last vaccination was study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3. |
| Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | Day 21 after last vaccination | Blood was collected from participants 21 days after the last vaccination for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. Each sample was tested according to standard operating procedures. A participant is counted if the value at the Day 63 timepoint was 1:40 or greater. Day 21 after last vaccination is study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3. |
| Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | Day 21 after last vaccination | Blood was collected from participants 21 days after the last vaccination for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. Each sample was tested according to standard operating procedures. A participant is counted if the value at the Day 63 timepoint was 1:40 or greater. Day 21 after last vaccination is study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3. |
| Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | Day 21 after last vaccination | Blood was collected from participants 21 days after the last vaccination for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. Each sample was tested according to standard operating procedures. A participant is counted if the value at the Day 63 timepoint was 1:40 or greater. Day 21 after last vaccination is study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3. |
| Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | Day 21 after the second H1N1 vaccination | Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, 21 days after second H1N1 vaccination is study Day 63, all others it is study Day 42. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | Day 21 after the second H1N1 vaccination | Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, 21 days after second H1N1 vaccination is study Day 63, all others it is study Day 42. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | Day 21 after the second H1N1 vaccination | Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, 21 days after second H1N1 vaccination is study Day 63, all others it is study Day 42. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | Day 0 prior to first vaccination and 21 days after the second H1N1 vaccination | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post second H1N1 vaccination is study Day 63 for Group 4, and is study Day 42 for all other groups. |
| Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | Day 0 prior to first vaccination and 21 days after the second H1N1 vaccination | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post second H1N1 vaccination is study Day 63 for Group 4, and is study Day 42 for all other groups. |
| Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | Day 0 prior to first vaccination and 21 days after the second H1N1 vaccination | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post second H1N1 vaccination is study Day 63 for Group 4, and is study Day 42 for all other groups. |
| Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | Day 0 prior to first vaccination and 21 days after last vaccination | Blood was collected from participants for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the titer at 21 days after last vaccination was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the titer at 21 days after last vaccination was an increase by 4-fold or more. Day 21 after last vaccination was study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3. |
Countries
United States
Participant flow
Recruitment details
Participants were healthy males and females, age 6 months to 17 years, recruited from existing volunteer populations and from the communities at large around the clinical sites. Participants were enrolled between 20AUG2009 and 21SEP2009.
Participants by arm
| Arm | Count |
|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV Participants received 15 mcg H1N1 Vaccine on Day 0; 15 mcg H1N1 Vaccine on Day 21, and Trivalent Influenza Vaccine (TIV) on Day 42 | 133 |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 Participants received 15 mcg H1N1 Vaccine + Trivalent Influenza Vaccine (TIV) on Day 0 and 15 mcg H1N1 Vaccine on Day 21 | 133 |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV Participants received 15 mcg H1N1 Vaccine on Day 0 and 15 mcg H1N1 Vaccine + Trivalent Influenza Vaccine (TIV) on Day 21 | 133 |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 Participants received Trivalent Influenza Vaccine (TIV) on Day 0; 15 mcg H1N1 Vaccine on Day 21, and 15 mcg H1N1 Vaccine on Day 42. | 132 |
| Total | 531 |
Baseline characteristics
| Characteristic | Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 133 Participants | 133 Participants | 133 Participants | 132 Participants | 531 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age Continuous | 8.2 years STANDARD_DEVIATION 5.3 | 7.9 years STANDARD_DEVIATION 5.3 | 8.0 years STANDARD_DEVIATION 5 | 8.5 years STANDARD_DEVIATION 5 | 8.1 years STANDARD_DEVIATION 5.1 |
| Region of Enrollment United States | 133 participants | 133 participants | 133 participants | 132 participants | 531 participants |
| Sex: Female, Male Female | 71 Participants | 57 Participants | 68 Participants | 57 Participants | 253 Participants |
| Sex: Female, Male Male | 62 Participants | 76 Participants | 65 Participants | 75 Participants | 278 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 124 / 133 | 125 / 133 | 124 / 133 | 125 / 132 |
| serious Total, serious adverse events | 0 / 133 | 3 / 133 | 1 / 133 | 2 / 132 |
Outcome results
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4.
Time frame: Within 8 days (Day 0-7) post first H1N1 vaccination
Population: All participants receiving the first H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 6 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 4 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 6 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 15 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 6 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 14 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 6 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4.
Time frame: Within 8 days (Day 0-7) post second H1N1 vaccination
Population: All participants receiving the second H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 15 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 13 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 14 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 9 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 13 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 4 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3.
Time frame: Within 8 days (Day 0-7) post TIV vaccination
Population: All participants receiving the TIV vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 15 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 4 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 10 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 15 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 9 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 15 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 11 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination
Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post first vaccination
Population: All participants receiving the first vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 0 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 0 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 0 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 1 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 1 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 2 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 2 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination
Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post second vaccination
Population: All participants receiving the second vaccination are included in the safety cohort. One Group 3 participant did not report temperatures. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 3 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 0 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 1 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 1 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 1 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 1 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 2 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination
Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. Groups 1 and 4 only had a third vaccination day.
Time frame: Within 8 days (Day 0-7) post third vaccination
Population: All participants receiving the third vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Fever | 0 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Vomiting | 0 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Vomiting | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Fever | 1 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4.
Time frame: Within 8 days (Day 0-7) post first H1N1 vaccination
Population: All participants receiving the first H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 16 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 22 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 11 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 3 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 10 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 13 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 6 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 18 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 14 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 6 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 15 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4.
Time frame: Within 8 days (Day 0-7) post second H1N1 vaccination
Population: All participants receiving the second H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 4 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 22 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 16 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 16 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 14 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 19 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 23 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 9 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 15 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 7 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 4 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3.
Time frame: Within 8 days (Day 0-7) post TIV vaccination
Population: All participants receiving the TIV vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 25 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 4 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 27 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 27 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 28 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 32 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 26 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 9 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 26 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 11 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 34 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post first vaccination
Population: All participants receiving the first vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Feverishness | 4 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Malaise | 14 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Myalgia | 8 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Headache | 11 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Nausea | 4 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased general activity | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased general activity | 10 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Headache | 17 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Feverishness | 7 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Myalgia | 9 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Malaise | 13 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Nausea | 9 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Malaise | 10 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Myalgia | 5 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Headache | 11 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased general activity | 6 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Nausea | 7 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Feverishness | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Nausea | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased general activity | 7 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Malaise | 11 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Headache | 12 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Feverishness | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Myalgia | 5 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post second vaccination
Population: All participants receiving the second vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Feverishness | 6 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Malaise | 9 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Myalgia | 7 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Headache | 15 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Nausea | 11 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased general activity | 7 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased general activity | 6 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Headache | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Feverishness | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Myalgia | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Malaise | 9 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Nausea | 5 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Malaise | 4 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Myalgia | 5 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Headache | 11 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased general activity | 4 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Nausea | 3 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Feverishness | 4 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Nausea | 3 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased general activity | 4 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Malaise | 2 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Headache | 8 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Feverishness | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Myalgia | 5 Participants |
Primary
Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Groups 1 and 4 only had a third vaccination day.
Time frame: Within 8 days (Day 0-7) post third vaccination
Population: All participants receiving the third vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Feverishness | 5 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Malaise | 8 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Myalgia | 3 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Headache | 9 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Nausea | 4 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Decreased general activity | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Nausea | 3 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Feverishness | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Headache | 7 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Malaise | 4 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Decreased general activity | 4 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Myalgia | 4 Participants |
Primary
Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post first H1N1 vaccination is Study Day 42 for Group 4, and is Study Day 21 for all other groups.
Time frame: Day 0 prior to vaccination and 21 days after the first H1N1 vaccination
Population: Participants who received the H1N1 vaccination and from whom blood was collected at the timepoint, both within 4 days of the window, are included. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 46 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 39 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 41 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 48 Participants |
Primary
Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, this timepoint is Study Day 42, all others it is Study Day 21. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater.
Time frame: Day 21 after first H1N1 vaccination
Population: Participants who received the H1N1 vaccination and from whom blood was collected at the timepoint, both within 4 days of the window, are included. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 47 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 40 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 45 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 48 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4.
Time frame: Within 8 days (Day 0-7) post first H1N1 vaccination
Population: All participants receiving the first H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 19 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 12 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 12 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 18 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 23 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 9 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 16 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 8 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4.
Time frame: Within 8 days (Day 0-7) post second H1N1 vaccination
Population: All participants receiving the second H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 8 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 12 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 19 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 9 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 22 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 11 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 10 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 18 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3.
Time frame: Within 8 days (Day 0-7) post TIV vaccination
Population: All participants receiving the TIV vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 16 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 14 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 19 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 20 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 10 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 18 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 10 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination
Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post first vaccination
Population: All participants receiving the first vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 4 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 9 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 0 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 1 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 5 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 3 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 1 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 1 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination
Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post second vaccination
Population: All participants receiving the second vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 4 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 1 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 2 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 2 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 1 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination
Participants or their parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. Groups 1 and 4 only had a third vaccination day.
Time frame: Within 8 days (Day 0-7) post third vaccination
Population: All participants receiving the third vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Fever | 0 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Vomiting | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Fever | 0 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Vomiting | 0 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4.
Time frame: Within 8 days (Day 0-7) post first H1N1 vaccination
Population: All participants receiving the first H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 16 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 11 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 15 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 10 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 26 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 13 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 9 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 21 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 13 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 21 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 8 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 14 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4.
Time frame: Within 8 days (Day 0-7) post second H1N1 vaccination
Population: All participants receiving the second H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 20 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 8 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 16 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 23 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 14 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 17 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 9 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 20 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 10 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 9 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 21 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3.
Time frame: Within 8 days (Day 0-7) post TIV vaccination
Population: All participants receiving the TIV vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 21 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 7 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 21 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 14 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 23 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 23 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 20 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 8 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 24 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 16 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 30 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post first vaccination
Population: All participants receiving the first vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Nausea | 8 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Myalgia | 5 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased general activity | 12 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Headache | 13 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Feverishness | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Nausea | 4 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Headache | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased general activity | 6 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Myalgia | 4 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Feverishness | 8 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Feverishness | 10 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Myalgia | 11 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Headache | 12 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Nausea | 6 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased general activity | 14 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Feverishness | 1 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased general activity | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Headache | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Myalgia | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Nausea | 4 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post second vaccination
Population: All participants receiving the second vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Nausea | 3 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased general activity | 3 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Myalgia | 5 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Headache | 5 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Feverishness | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Headache | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Nausea | 3 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Myalgia | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Feverishness | 3 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased general activity | 6 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased general activity | 6 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Feverishness | 4 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Myalgia | 3 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Headache | 4 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Nausea | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Feverishness | 2 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Nausea | 0 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Headache | 2 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Myalgia | 3 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased general activity | 4 Participants |
Primary
Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination
Participants or their parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, myalgia, headache, nausea and decreased general activity for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Groups 1 and 4 only had a third vaccination day.
Time frame: Within 8 days (Day 0-7) post third vaccination
Population: All participants receiving the third vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Myalgia | 2 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Nausea | 1 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Headache | 2 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Decreased general activity | 3 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Feverishness | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Decreased general activity | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Feverishness | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Myalgia | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Headache | 3 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Nausea | 1 Participants |
Primary
Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post first H1N1 vaccination is Study Day 42 for Group 4, and is Study Day 21 for all other groups.
Time frame: Day 0 prior to vaccination and 21 days after the first H1N1 vaccination
Population: Participants who received the H1N1 vaccination and from whom blood was collected at the timepoint, both within 4 days of the window, are included. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 20 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 21 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 19 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 20 Participants |
Primary
Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, this timepoint is Study Day 42, all others it is Study Day 21. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater.
Time frame: Day 21 after first H1N1 vaccination
Population: Participants who received the H1N1 vaccination and from whom blood was collected at the timepoint, both within 4 days of the window, are included. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 20 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 21 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 19 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 22 Participants |
Primary
Number of Participants Age 6 Months to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post first H1N1 vaccination is Study Day 42 for Group 4, and is Study Day 21 for all other groups.
Time frame: Day 0 prior to vaccination and 21 days after the first H1N1 vaccination
Population: Participants who received the H1N1 vaccination and from whom blood was collected at the timepoint, both within 4 days of the window, are included. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 Months to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 10 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 Months to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 6 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 Months to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 Months to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 5 Participants |
Primary
Number of Participants Age 6 Months to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, this timepoint is Study Day 42, all others it is Study Day 21. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater.
Time frame: Day 21 after first H1N1 vaccination
Population: Participants who received the H1N1 vaccination and from whom blood was collected at the timepoint, both within 4 days of the window, are included. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 Months to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 10 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 Months to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 6 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 Months to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 Months to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine | 5 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination
Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they were reported as experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4.
Time frame: Within 8 days (Day 0-7) post first H1N1 vaccination
Population: All participants receiving the first H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 14 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 4 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 10 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 15 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 15 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Redness | 17 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the First H1N1 Vaccination | Swelling | 9 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination
Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they were reported as experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4.
Time frame: Within 8 days (Day 0-7) post second H1N1 vaccination
Population: All participants receiving the second H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 14 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 7 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 17 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 8 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 9 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 14 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Swelling | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the Second H1N1 Vaccination | Redness | 14 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination
Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of swelling and redness for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they were reported as experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3.
Time frame: Within 8 days (Day 0-7) post TIV vaccination
Population: All participants receiving the TIV vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 17 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 6 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 9 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 14 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 16 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 9 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Redness | 17 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Local Reactions After the TIV Vaccination | Swelling | 9 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination
Participants' parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post first vaccination
Population: All participants receiving the first vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 2 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 1 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 2 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 3 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 3 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Fever | 3 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the First Vaccination | Vomiting | 2 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination
Participants' parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post second vaccination
Population: All participants receiving the second vaccination are included in the safety cohort. One Group 2 participant did not report temperatures. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 3 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 0 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 1 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 4 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 3 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Fever | 1 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Second Vaccination | Vomiting | 2 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination
Participants' parents/guardians maintained a memory aid to record daily oral/axillary temperatures and the number of vomiting episodes, if experienced, for 8 days after vaccination (Day 0-7). Participants are counted as experiencing fever if they reported oral temperatures of 38.3 degrees Celsius or higher, or axillary temperatures of 37.8 degrees Celsius or higher, on any of the 8 days. Participants are counted as experiencing vomiting if they reported one or more episodes of vomiting on any of the 8 days. Groups 1 and 4 only had a third vaccination day.
Time frame: Within 8 days (Day 0-7) post third vaccination
Population: All participants receiving the third vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Fever | 3 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Vomiting | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Fever | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Quantitative Systemic Reactions After the Third Vaccination | Vomiting | 0 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination
Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. First H1N1 vaccination was given on Study Day 0 for Groups 1, 2 and 3, and on Study Day 21 for Group 4.
Time frame: Within 8 days (Day 0-7) post first H1N1 vaccination
Population: All participants receiving the first H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 1 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 4 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 11 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 6 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 10 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 11 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 8 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 15 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Pain | 1 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Swelling | 7 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the First H1N1 Vaccination | Tenderness | 9 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination
Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Second H1N1 vaccination was given on Study Day 21 for Groups 1, 2 and 3, and on Study Day 42 for Group 4.
Time frame: Within 8 days (Day 0-7) post second H1N1 vaccination
Population: All participants receiving the second H1N1 vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 6 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 8 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 4 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 7 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 5 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 10 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 18 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 6 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Tenderness | 9 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Swelling | 4 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the Second H1N1 Vaccination | Pain | 1 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination
Participants' parents/guardians maintained a memory aid to record daily the occurrence of local reactions of pain, tenderness and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. The TIV vaccination was given on Study Day 42 for Group 1, Study Day 0 for Groups 2 and 4, and on Study Day 21 for Group 3.
Time frame: Within 8 days (Day 0-7) post TIV vaccination
Population: All participants receiving the TIV vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 6 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 3 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 9 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 10 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 6 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 7 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 15 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 7 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Swelling | 7 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Tenderness | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Local Reactions After the TIV Vaccination | Pain | 1 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination
Participants' parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of irritability, decreased appetite and lethargy for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post first vaccination
Population: All participants receiving the first vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Irritability | 18 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Lethargy | 8 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased appetite | 6 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Irritability | 15 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Lethargy | 6 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased appetite | 5 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased appetite | 9 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Irritability | 16 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Lethargy | 8 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Irritability | 9 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Lethargy | 3 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the First Vaccination | Decreased appetite | 5 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination
Participants' parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of irritability, decreased appetite and lethargy for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days.
Time frame: Within 8 days (Day 0-7) post second vaccination
Population: All participants receiving the second vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Lethargy | 6 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Irritability | 11 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased appetite | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Lethargy | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased appetite | 5 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Irritability | 15 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Irritability | 13 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased appetite | 3 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Lethargy | 4 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Lethargy | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Irritability | 11 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Second Vaccination | Decreased appetite | 7 Participants |
Primary
Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Third Vaccination
Participants' parents/guardians maintained a memory aid to record daily the occurrence of systemic symptoms of irritability, decreased appetite and lethargy for 8 days after vaccination (Day 0-7) based on their interference with daily activities. Participants are counted if they were reported as experiencing the symptom at any severity on any of the 8 days. Groups 1 and 4 only had a third vaccination day.
Time frame: Within 8 days (Day 0-7) post third vaccination
Population: All participants receiving the third vaccination are included in the safety cohort. Analyses are as treated. This outcome measure is restricted to protocol-defined age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Irritability | 9 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Decreased appetite | 5 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Lethargy | 6 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Irritability | 8 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Decreased appetite | 2 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months Reporting Solicited Subjective Systemic Reactions After the Third Vaccination | Lethargy | 2 Participants |
Primary
Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs)
Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required in-patient hospitalization or prolongation thereof; resulted in a congenital anomaly/birth defect; may have jeopardized the participant or required intervention to prevent one of these outcomes; or was described as Guillain-Barré Syndrome. Association to vaccination was determined by a study clinician licensed to make medical diagnoses.
Time frame: Day 0 through 180 days after the last vaccination
Population: All participants receiving at least one vaccination are included in the safety cohort. Analyses are as treated.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) | 0 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) | 0 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) | 0 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) | 0 Participants |
Secondary
Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post second H1N1 vaccination is study Day 63 for Group 4, and is study Day 42 for all other groups.
Time frame: Day 0 prior to first vaccination and 21 days after the second H1N1 vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 48 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 41 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 43 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 50 Participants |
Secondary
Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination
Blood was collected from participants for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the titer at 21 days after last vaccination was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the titer at 21 days after last vaccination was an increase by 4-fold or more. Day 21 after last vaccination was study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3.
Time frame: Day 0 prior to first vaccination and Day 21 after last vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 35 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 36 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 34 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 28 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 22 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 33 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 28 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 24 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 25 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 33 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 32 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 30 Participants |
Secondary
Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, 21 days after second H1N1 vaccination is study Day 63, all others it is study Day 42. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater.
Time frame: Day 21 after the second H1N1 vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 49 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 42 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 47 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 50 Participants |
Secondary
Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination
Blood was collected from participants 21 days after the last vaccination for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. Each sample was tested according to standard operating procedures. A participant is counted if the value at the Day 63 timepoint was 1:40 or greater. Day 21 after last vaccination is study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3.
Time frame: Day 21 after last vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 49 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 47 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 49 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 46 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 35 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 46 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 46 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 40 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 46 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 50 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 47 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 10 to 17 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 50 Participants |
Secondary
Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post second H1N1 vaccination is study Day 63 for Group 4, and is study Day 42 for all other groups.
Time frame: Day 0 prior to first vaccination and 21 days after the second H1N1 vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. One participant was excluded due to receipt of a non-study vaccine and one due to Influenza-like illness. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 38 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 37 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 36 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 35 Participants |
Secondary
Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination
Blood was collected from participants for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the titer at 21 days after last vaccination was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the titer at 21 days after last vaccination was an increase by 4-fold or more. Day 21 after last vaccination was study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3.
Time frame: Day 0 prior to first vaccination and Day 21 after last vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. One participant was excluded due to receipt of non-study vaccine, 3 due to Influenza-like illness, and 1 due to H1N1 infection. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 27 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 26 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 30 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 20 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 19 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 30 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 23 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 16 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 21 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 24 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 21 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 29 Participants |
Secondary
Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, 21 days after second H1N1 vaccination is study Day 63, all others it is study Day 42. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater.
Time frame: Day 21 after the second H1N1 vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. One participant was excluded due to receipt of a non-study vaccine and one due to Influenza-like illness. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 38 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 37 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 36 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 37 Participants |
Secondary
Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination
Blood was collected from participants 21 days after the last vaccination for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. Each sample was tested according to standard operating procedures. A participant is counted if the value at the Day 63 timepoint was 1:40 or greater. Day 21 after last vaccination is study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3.
Time frame: Day 21 after last vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. One participant was excluded due to receipt of non-study vaccine, 3 due to Influenza-like illness, and 1 due to H1N1 infection. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 38 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 32 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 38 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 43 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 31 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 43 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 44 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 44 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 33 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 47 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 34 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 36 Months to 9 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 47 Participants |
Secondary
Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. Day 21 post second H1N1 vaccination is study Day 63 for Group 4, and is study Day 42 for all other groups.
Time frame: Day 0 prior to first vaccination and 21 days after the second H1N1 vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. One participant was excluded due to receipt of a non-study vaccine and one due to Influenza-like illness. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 23 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 23 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 26 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 19 Participants |
Secondary
Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination
Blood was collected from participants for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the titer at 21 days after last vaccination was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the titer at 21 days after last vaccination was an increase by 4-fold or more. Day 21 after last vaccination was study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3.
Time frame: Day 0 prior to first vaccination and 21 days after last vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. Two participants were excluded due to receipt of non-study vaccines and one due to Influenza-like illness. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 23 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 10 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 25 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 14 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 7 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 18 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 25 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 19 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 4 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 18 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 4 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 23 Participants |
Secondary
Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. For Group 4, 21 days after second H1N1 vaccination is study Day 63, all others it is study Day 42. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater.
Time frame: Day 21 after the second H1N1 vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. One participant was excluded due to receipt of a non-study vaccine and one due to Influenza-like illness. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 23 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 24 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 26 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine | 19 Participants |
Secondary
Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination
Blood was collected from participants 21 days after the last vaccination for testing in the HAI assay against each strain in the 2009-2010 trivalent influenza vaccine. Each sample was tested according to standard operating procedures. A participant is counted if the value at the Day 63 timepoint was 1:40 or greater. Day 21 after last vaccination is study Day 63 for Groups 1 and 4, and study Day 42 for Groups 2 and 3.
Time frame: Day 21 after last vaccination
Population: Participants who received all vaccinations and from whom blood was collected at the timepoint, all within 4 days of the window, are included. Two participants were excluded due to receipt of non-study vaccines and one due to Influenza-like illness. Analyses are as treated. This outcome restricts to age stratum.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 29 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 10 Participants |
| Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 29 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 30 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 9 Participants |
| Group 2: Day 0-H1N1+TIV; Day 21-H1N1 | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 30 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 29 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 29 Participants |
| Group 3: Day 0-H1N1; Day 21-H1N1+TIV | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 8 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H1 antigen | 24 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV B antigen | 5 Participants |
| Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 | Number of Participants Age 6 to Less Than 36 Months With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Virus Strains in the 2009-2010 Trivalent Influenza Vaccine (TIV) 21 Days Following the Last Vaccination | TIV H3 antigen | 25 Participants |